Gain Therapeutics, Inc. - Common Stock — Balance Sheet (NASDAQ:GANX) | MetaTrader

Open full chart Full chart

Financials

Overview Statement Statistics

Quarterly Annual

Total assets 38.99 M24.1 M18.61 M12.12 M22.82 M Total liabilities 4.17 M5.22 M6.03 M4.78 M4.25 M Total equity 34.82 M18.88 M12.58 M7.34 M18.56 M Total liabilities & shareholders' equities 38.99 M24.1 M18.61 M12.12 M22.82 M Total debt 590.47 K495.26 K449.05 K328.33 K400.95 K Net debt 590.47 K495.26 K-16.35 M328.33 K-20.54 M

News

Gain Therapeutics reports 81% reduction in Parkinson’s biomarker

Why GH Research Shares Are Trading Higher By 18%; Here Are 20 Stocks Moving Premarket - BioAtla (NASDAQ:BCAB), ChowChow Cloud Internatio (AMEX:CHOW)

Gain Therapeutics (GANX) Upgraded to Buy: Here's Why

U.S. stocks higher at close of trade; Dow Jones Industrial Average up 0.14%

Is Enhabit, Inc. (EHAB) Stock Outpacing Its Medical Peers This Year?

Here's Why Gain Therapeutics, Inc. (GANX) is a Great Momentum Stock to Buy

H.C. Wainwright reiterates Buy rating on Gain Therapeutics stock ahead of trial data

Gain Therapeutics files prospectus supplement for $35.5 million stock offering

Gain Therapeutics (GANX) Upgraded to Buy: Here's What You Should Know

Gain Therapeutics stock rating reiterated at Buy by H.C. Wainwright

Gain Therapeutics reports preliminary Phase 1b data for Parkinson’s drug GT-02287

Gain Therapeutics reports positive early data from Parkinson’s trial